Cs Diagnostics CORP

CS Diagnostics Corp. converted all Series B Preferred Stock held by affiliates into 112.65 million common shares to streamline its capital structure and enable consolidated financial reporting by year-end 2025.

CS Diagnostics Corp. filed an 8-K report detailing its focus on innovative medical solutions, particularly the CS Protect Hydrogel for radiation therapy.

CS Diagnostics Corp. achieved increased net income for the nine months ended September 30, 2025, driven by significant cost reductions, despite an 11% decrease in revenue.

CS Diagnostics Corp. reported a significant increase in net income for Q2 2025, driven by substantial cost reductions, despite a notable decline in revenue.

CS Diagnostics Corp. reported a significant increase in revenue for fiscal year 2025, primarily due to an Affiliate Revenue Agreement, while facing ongoing liquidity constraints and a material weakness in internal controls.

Antonio Santoli has disclosed a 9.9% beneficial ownership stake in CS Diagnostics Corp., primarily through common and convertible Series B Preferred Stock.

Thomas Graus has reported a 9.9% beneficial ownership stake in CS DIAGNOSTICS CORP., comprising common stock and convertible Series B Preferred Stock.